Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
- Conditions
- HIV-1 InfectionKaposi's Sarcoma
- Interventions
- Drug: efavirenz/emtricitabine/tenofovir disoproxil fumarateDrug: etoposide
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 192
- Registration Number
- NCT01352117
- Locations
- 🇰🇪
Walter Reed Project - Kenya Med. Research Institute Kericho CRS (12501), Kericho, Kenya
🇺🇬JCRC CRS, Kampala, Uganda
🇲🇼University of North Carolina Lilongwe CRS (12001), Lilongwe, Malawi
Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Adult Acute Monoblastic Leukemia (M5a)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Megakaryoblastic Leukemia (M7)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)
- Interventions
- Drug: cyclosporineDrug: pravastatin sodiumDrug: mitoxantrone hydrochlorideDrug: etoposideProcedure: bone marrow aspiration
- First Posted Date
- 2011-04-27
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT01342887
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
- Conditions
- Anaplastic Large Cell LymphomaHepatosplenic T-cell LymphomaAngioimmunoblastic T-cell LymphomaPeripheral T-cell Lymphoma
- Interventions
- Drug: prednisoneDrug: cyclophosphamideDrug: etoposideDrug: VincristineDrug: pralatrexateOther: laboratory biomarker analysisGenetic: comparative genomic hybridizationGenetic: gene expression analysisGenetic: nucleic acid sequencingGenetic: mutation analysisOther: immunohistochemistry staining methodGenetic: microarray analysisGenetic: RNA analysis
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 34
- Registration Number
- NCT01336933
- Locations
- 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT01331590
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas
- Conditions
- Lymphoma
- Interventions
- Drug: OfatumumabDrug: IfosfamideDrug: EtoposideDrug: MesnaDrug: G-CSFProcedure: Stem Cell Collection
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT01329900
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia
- Conditions
- Adult Acute Eosinophilic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Myeloid Leukemia in RemissionAdult Acute Myelomonocytic LeukemiaAdult Acute Basophilic LeukemiaUntreated Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With MaturationAdult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL
- Interventions
- Drug: AzacitidineDrug: EtoposideOther: Laboratory Biomarker AnalysisDrug: Mitoxantrone Hydrochloride
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT01260714
- Locations
- 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response
- Conditions
- OsteosarcomaLung Metastases
- Interventions
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 2
- Registration Number
- NCT01258634
- Locations
- 🇺🇸
University of Chicago Department of Pediatrics Hematology/Oncology, Chicago, Illinois, United States
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Interventions
- Biological: AlemtuzumabProcedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CyclophosphamideDrug: CytarabineDrug: DasatinibDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Etoposide PhosphateBiological: FilgrastimDrug: Fludarabine PhosphateProcedure: In Vitro-Treated Peripheral Blood Stem Cell TransplantationOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: MelphalanDrug: MercaptopurineDrug: MethotrexateBiological: PegfilgrastimOther: Pharmacological StudyDrug: TacrolimusDrug: Vincristine Sulfate
- First Posted Date
- 2010-12-08
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT01256398
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States
🇺🇸Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States
🇺🇸Longmont United Hospital, Longmont, Colorado, United States
Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2010-12-01
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Fondazione Michelangelo
- Target Recruit Count
- 331
- Registration Number
- NCT01251107
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale di Tumori di Milano, Milano, Italy
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Refractory Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid Leukemia
- Interventions
- Drug: AzacitidineDrug: CytarabineDrug: Etoposide PhosphateOther: Laboratory Biomarker AnalysisDrug: Mitoxantrone HydrochlorideOther: Pharmacological Study
- First Posted Date
- 2010-11-29
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT01249430
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.